NCT00518102View on ClinicalTrials.gov

The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

CompletedOBSERVATIONAL
Enrollment

4,431

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Diabetes Mellitus
Interventions
DRUG

REGRANEX (becaplermin)

A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).

OTHER

REGRANEX (becaplermin) comparators

A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT00518102 - The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin]) | Biotech Hunter | Biotech Hunter